drugset / Trial / NCT01929070

A Pilot Study to Evaluate the Pharmacokinetics of Omega-3 Between Rosuvastatin and Omega-3 Coadministration and HCP1007

NCT01929070

Phase 1 Completed 12 enrolled Hanmi Pharmaceutical Company Limited
RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study is to evaluate the pharmacokinetics of omega-3 between rosuvastatin and omega-3 coadministration and HCP1007 in healthy male volunteers.

Timeline

Start
2013-02
Primary completion
2013-03
Completion
2013-03

Drugs

EvaluationDrugModalityDoseRoute
Subject HCP1007 Unknown
Subject Lovaza Other / unclassified 4 g
Subject Rosuvastatin Small molecule 20 mg

Indications

No indication recorded.